Download the free e-book on peptides, hormones and pharmaceuticals for longevity, health and performance here: get the e-book
For decades the relationship between testosterone and cardiovascular health was framed primarily as a concern. Testosterone, and particularly testosterone replacement therapy, was viewed with suspicion in cardiology circles, associated in the clinical imagination with the aggressive behavior and cardiovascular risk that high-dose anabolic steroid use in athletes had generated in the research literature.
That framing was always an oversimplification. And the accumulation of evidence over the past decade, culminating in landmark clinical trials that were specifically designed to answer the cardiovascular safety question, has shifted the scientific consensus in ways that have significant implications for how testosterone optimization is discussed and practiced.
Where the concern came from
The cardiovascular concern around testosterone did not emerge from nothing. Several observational studies in the early 2010s reported associations between testosterone therapy and increased rates of cardiovascular events including heart attack and stroke. These studies received significant media attention and contributed to a climate of caution around testosterone prescribing that persisted for years.
The methodological problems with these studies were substantial. They were observational rather than randomized, meaning they could identify associations but not causation. They were confounded by the fact that men seeking testosterone therapy are often older, more sedentary, and carry more cardiovascular risk factors at baseline than the general population, making it difficult to separate the effect of the therapy from the pre-existing risk profile of the men receiving it. And several of the most cited studies had significant data quality issues that were identified and criticized in subsequent analyses.
The picture they painted was concerning enough to prompt regulatory action and clinical caution. It was not, as subsequent research has demonstrated, an accurate representation of testosterone's actual cardiovascular effects in appropriately selected patients.
The TRAVERSE trial
The definitive answer to the testosterone and cardiovascular safety question came from the TRAVERSE trial, a large randomized placebo-controlled trial specifically designed to assess cardiovascular outcomes in men with low testosterone and pre-existing cardiovascular disease or high cardiovascular risk.
This is the trial that the field needed. It enrolled over 5,000 men, followed them for a median of 33 months, and measured major adverse cardiovascular events including heart attack, stroke, and cardiovascular death as its primary endpoint.
The result was cardiovascular non-inferiority. Men treated with testosterone gel had the same rate of major cardiovascular events as men receiving placebo. Testosterone replacement therapy did not increase cardiovascular risk in this high-risk population.
This finding is significant for two reasons. First, it directly addressed and largely put to rest the cardiovascular concern that had been limiting appropriate testosterone prescribing for years. Second, it did so in a population with pre-existing cardiovascular disease or high cardiovascular risk, meaning the result is applicable to the men who were most concerning from a cardiovascular standpoint, not just healthy low-risk individuals.
What testosterone actually does for cardiovascular health
Beyond the safety question, there is a separate and important conversation about what testosterone's biological effects on the cardiovascular system actually are, which points in a more positive direction than the historical narrative suggested.
Testosterone has vasodilatory effects on coronary and peripheral arteries, improving blood flow through mechanisms that involve nitric oxide signaling and direct effects on vascular smooth muscle. Men with low testosterone consistently show higher rates of endothelial dysfunction, the impaired vascular response that is an early marker of cardiovascular disease, than men with optimal testosterone levels.
The relationship between testosterone and metabolic health is central to understanding its cardiovascular implications. Testosterone supports insulin sensitivity, promotes lean mass development at the expense of fat mass, and reduces visceral fat accumulation. All three of these effects directly reduce cardiovascular risk through their impact on the metabolic syndrome components that are among the strongest drivers of cardiovascular disease.
Low testosterone in men is consistently associated in the epidemiological literature with higher rates of metabolic syndrome, type 2 diabetes, and cardiovascular disease. Whether low testosterone causes these conditions, results from them, or is a marker of the same underlying metabolic dysfunction that drives them is a complex question that the research has not fully resolved. But the association is robust and consistent across large population studies.
The atrial fibrillation finding
The TRAVERSE trial did identify one signal worth noting honestly. Men on testosterone therapy had a higher rate of atrial fibrillation compared to placebo, approximately 3.5 percent versus 2.4 percent over the study period. This did not translate into higher rates of stroke or cardiovascular death, and the absolute difference was modest, but it is a finding that should inform clinical discussion particularly for men with pre-existing atrial fibrillation or significant risk factors for it.
The mechanism behind this finding is not fully understood. Testosterone's effects on cardiac electrical conduction and on cardiac muscle directly may play a role. For most men the clinical significance of this finding is limited, but for men with atrial fibrillation history or significant AF risk factors it warrants specific discussion with a cardiologist before beginning testosterone therapy.
The pulmonary embolism question
The TRAVERSE trial also identified a higher rate of pulmonary embolism in the testosterone group compared to placebo. This is thought to be related to testosterone's effect on erythropoiesis, the production of red blood cells, which increases hematocrit and can increase blood viscosity and clotting risk in susceptible individuals.
This is why monitoring hematocrit is a standard part of responsible testosterone therapy management. When hematocrit rises above threshold levels, dose adjustment or therapeutic phlebotomy are used to maintain levels within a safe range. This risk is manageable with appropriate monitoring and does not represent a reason to avoid testosterone therapy in appropriate candidates, but it does represent a reason why monitoring matters and why self-administered testosterone without clinical oversight carries real risk.
Testosterone and cardiac muscle
Beyond vascular effects, testosterone has direct effects on cardiac muscle that are relevant to long-term cardiovascular health. Testosterone receptors are expressed in cardiac tissue, and testosterone influences cardiac muscle mass, contractility, and the cellular processes involved in cardiac remodeling.
In physiological ranges, testosterone's effects on the heart are generally considered beneficial, supporting cardiac muscle maintenance and function in ways that are consistent with its broader anabolic effects on skeletal muscle. At supraphysiologic levels, such as those associated with high-dose anabolic steroid use rather than therapeutic testosterone replacement, the cardiac effects become more complex and potentially adverse, including pathological cardiac hypertrophy and fibrosis.
This distinction between physiological testosterone replacement and supraphysiologic anabolic steroid use is central to interpreting the cardiovascular research correctly. The two are not the same intervention and the cardiovascular risks associated with one do not automatically apply to the other.
The practical implications
The clinical picture that emerges from the current evidence base is considerably more reassuring than the narrative of a decade ago.
Testosterone replacement therapy in appropriately selected men with low testosterone does not increase the risk of major cardiovascular events including heart attack and stroke. This is now supported by the highest level of clinical evidence available, a large randomized controlled trial specifically designed to answer this question.
Testosterone has biological effects on the cardiovascular system that are broadly favorable in physiological ranges, including vasodilatory effects, metabolic improvements, and support for cardiac muscle function.
Two specific risks warrant monitoring and clinical discussion: atrial fibrillation risk, particularly in men with pre-existing AF or significant risk factors, and hematocrit elevation, which requires regular monitoring and management as a standard part of responsible testosterone therapy.
For men with low testosterone who are experiencing the symptoms of hormonal decline, the cardiovascular safety concern that previously gave many physicians pause in prescribing is no longer supported by the best available evidence. The conversation has shifted from whether testosterone therapy is safe for the heart to how to use it responsibly in a way that captures its benefits while monitoring for the specific risks that require attention.
This content is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before making any changes to your health regimen. For more information visit www.peakformrx.health